Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

Scrip Asia 100 ebook

Citeline's latest Scrip Asia 100 e-book is live! Visit the microsite to download the report.


Spotlight On Earnings


Focus On Asia


Data Analysis


R&D


Value Of AbbVie’s Cerevel Buy Uncertain After Schizophrenia Failure

Value Of AbbVie’s Cerevel Buy Uncertain After Schizophrenia Failure

 
• By 

With two misses for emraclidine, AbbVie will hope to extract some value from the Cerevel acquisition from the Parkinson’s drug tavapadon, while BMS may get a big lead in the schizophrenia space.

Rapt Scraps Zelnecirnon, But Not Giving Up On CCR4

Rapt Scraps Zelnecirnon, But Not Giving Up On CCR4

 

The company said it does not see a development path for zelnecirnon based on feedback from the US FDA. It halted two Phase II trials in asthma and atopic dermatitis earlier this year.

Pipeline Watch: Sanofi/Regeneron’s Dupixent Gets EU Eosinophilic Esophagitis Approved For Young Children

Pipeline Watch: Sanofi/Regeneron’s Dupixent Gets EU Eosinophilic Esophagitis Approved For Young Children

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Tezspire Phase III Nasal Polyp Data May Lead To Second Indication

Tezspire Phase III Nasal Polyp Data May Lead To Second Indication

 
• By 

AstraZeneca and Amgen’s first-in-class anti-TSLP agent Tezspire, already approved for severe asthma, has shown an ability to reduce the size of nasal polyps and improve congestion.

Business


Eisai Cuts US Leqembi Sales Forecast But Japan, China Exceed Expectations

Eisai Cuts US Leqembi Sales Forecast But Japan, China Exceed Expectations

 
• By 

Eisai/Biogen’s Alzheimer’s disease medicine Leqembi has been a challenge to launch, but while access to pre-treatment testing has improved, infusion center capacity is impacting US sales.

Value Of AbbVie’s Cerevel Buy Uncertain After Schizophrenia Failure

Value Of AbbVie’s Cerevel Buy Uncertain After Schizophrenia Failure

 
• By 

With two misses for emraclidine, AbbVie will hope to extract some value from the Cerevel acquisition from the Parkinson’s drug tavapadon, while BMS may get a big lead in the schizophrenia space.

Muscling Into The Obesity Market

Muscling Into The Obesity Market

 

At a recent conference, executives from Boehringer and Amgen laid out their expectations for the future of obesity and how they intend to navigate the changes.

Almirall Insists Costly Ebglyss Launch Is Progressing Well

Almirall Insists Costly Ebglyss Launch Is Progressing Well

 
• By 

The Spanish company's Lilly-partnered atopic dermatitis drug is enjoying a decent launch in Germany and in other European countries, "we are getting the price that we wanted," claims CEO Carlos Gallardo.

Scrip Originals


Pipeline Watch: Sanofi/Regeneron’s Dupixent Gets EU Eosinophilic Esophagitis Approved For Young Children

Pipeline Watch: Sanofi/Regeneron’s Dupixent Gets EU Eosinophilic Esophagitis Approved For Young Children

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Deal Watch: Renexxion To Go Public While Avid Biosciences Goes Private

Deal Watch: Renexxion To Go Public While Avid Biosciences Goes Private

 
• By 

Plus deals involving Synaffix/BigHat, AbbVie/EvolveImmune, Servier/Aitia, Dr. Falk/Kynos, Bayer/Dewpoint and more.

Executives On The Move: Five CEOs And Four New CFOs Among This Week’s Changes

Executives On The Move: Five CEOs And Four New CFOs Among This Week’s Changes

 
• By 

Recent moves in the industry include C-suite changes at Coya Therapeutics, Kancera and Verrica Pharmaceuticals, which acquires chief financial officer from Aceragen.

Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals

Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals

 
• By 

Public Company Edition: Syndax received all $350m from its royalty financing up front, while KalVista got $100m initially out of up to $179m. Also, Vera, EyePoint and Eledon grossed $300m, $161m and $85m in follow-on offerings, while Neurogene raised $200m in a private placement.